Polyrizon's New Naloxone Hydrogel Enhances Mucoadhesion for Opioid Reversal

Written by Emily J. Thompson, Senior Investment Analyst

PLRZ.O-9.66%

Source: Newsfilter

Updated: 4 day ago

0mins

Source: Newsfilter

Enhanced Adhesion: Polyrizon's naloxone hydrogel demonstrated superior mucoadhesion in an ex-vivo rabbit nasal mucosa model compared to an approved nasal spray, achieving statistical significance at p<0.0001, indicating its potential advantages in emergency drug absorption.
Improved Bioavailability: The hydrogel's higher adhesion may prolong drug residence time in the nasal cavity, thereby enhancing bioavailability and supporting faster onset of action, which is critical in opioid overdose emergencies.
Technology Validation: CEO Tomer Izraeli emphasized that the new data further validates the potential of the T&T hydrogel platform, marking a significant milestone in advancing the naloxone program and potentially enhancing the company's market competitiveness.
Stability Reinforcement: The hydrogel's stability results under various storage conditions, combined with its adhesion performance, bolster Polyrizon's confidence in developing a safer and more effective naloxone product.

PLRZ.O

$0.0000%Past 6 months

Line

Candle

YTD

No Data

Intellectia

Analyst Views on PLRZ

About PLRZ

Polyrizon Ltd is an Israel-based biotechnology company. The Company is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The Company is focused not only on the development of intranasal products, but also on commercialization. The Company cooperates with medical specialists and researchers..

About the author

Preview

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.